Robert E. Waltermire - Jun 12, 2024 Form 4 Insider Report for MADRIGAL PHARMACEUTICALS, INC. (MDGL)

Role: Senior VP, Chief Pharma Dev.
Signature: /s/ Mardi Dier, as Attorney-in-Fact
Stock symbol: MDGL
Transactions as of: Jun 12, 2024
Transactions value $: -$394,160
Form type: 4
Date filed: 6/14/2024, 09:44 PM
Previous filing: May 23, 2024
Next filing: Jun 18, 2024

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	MDGL	Common Stock	Options Exercise	$176K	+2K	+36.36%	$87.92	7.5K	Jun 12, 2024	Direct	F1
transaction	MDGL	Common Stock	Sale	-$570K	-2K	-26.67%	$285.00	5.5K	Jun 12, 2024	Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	MDGL	Stock Option (Right to Buy)	Options Exercise	$0	-2K	-11.63%	$0.00	15.2K	Jun 12, 2024	Common Stock	2K	$87.92	Direct	F1

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	All shares issued pursuant to the exercise of the options reported herein represent 2,000 shares underlying an overall option award of 35,000 shares. All exercised options had vested. As to the overall option for 35,000 shares, 25% of the shares underlying the option vested on August 2, 2022 and, thereafter, 6.25% of the shares vested, or will vest, on the last day of each successive three-month period, provided the Reporting Person continues in service with the Issuer on each such date.

Content

All shares issued pursuant to the exercise of the options reported herein represent 2,000 shares underlying an overall option award of 35,000 shares. All exercised options had vested. As to the overall option for 35,000 shares, 25% of the shares underlying the option vested on August 2, 2022 and, thereafter, 6.25% of the shares vested, or will vest, on the last day of each successive three-month period, provided the Reporting Person continues in service with the Issuer on each such date.